How long can you take daratumumab?
Darzalex is administered until signs of progression of multiple myeloma (MM) occur, or side effects become intolerable. Treatment durations of up to 25 months have been reported in clinical trials (range 0.1 month to 40.44 months). Research suggests people with IgG MM may be more responsive to Darzalex treatment.
What is the success rate of daratumumab?
Daratumumab, Lenalidomide, and Dexamethasone The overall response rate was 81%, with 34% of patients achieving a complete response or better and 63% achieving a very good partial response (VGPR) or better. The median response duration was not reached, and 91% of patients were free of disease progression at 12 months.
How much does daratumumab cost?
However, daratumumab is a costly drug, priced at nearly $6,500 per infusion; as a result, it is unclear whether it provides sufficient value in this clinical setting.
Is Darzalex the same as daratumumab?
Darzalex is a brand-name prescription medication. It’s used to treat multiple myeloma, which is a type of cancer that affects certain white blood cells called plasma cells. Darzalex contains daratumumab. This is a type of drug called a monoclonal antibody.
Does Daratumumab cause neuropathy?
In this pooled safety population, the most common adverse reactions (≥20%) were upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia.
How many times can you go into remission from myeloma?
About one-fourth of people with relapsed multiple myeloma will go into remission after several cycles of chemo. Those who get targeted therapies or high-dose chemo followed by a stem cell transplant usually have better outcomes. Clinical trial. You might want to consider this if your cancer comes back.
Does daratumumab suppress immune system?
Daratumumab-mediated elimination of these CD38+ immune regulatory cells may reduce local immune suppression within the myeloma microenvironment and allow positive immune effector cells to expand and contribute to antitumor response.
What is daratumumab monotherapy?
Daratumumab is indicated for patients who have received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who are double refractory to a proteasome inhibitor and an immunomodulatory drug.
Is Daratumumab covered by Medicare?
With the Janssen CarePath Savings Program for DARZALEX®, eligible patients pay $5 for each infusion for your medication costs, with a $20,000 maximum program benefit each calendar year. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications.
Is Daratumumab considered chemotherapy?
DARZALEX® (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. DARZALEX® is not chemotherapy. It is a targeted monoclonal antibody that helps slow or stop the progression of multiple myeloma in several ways.
Does Daratumumab suppress immune system?
Does daratumumab cause insomnia?
The most common adverse reactions (≥20%) were upper respiratory tract infection, constipation, nausea, fatigue, pyrexia, peripheral sensory neuropathy, diarrhea, cough, insomnia, vomiting, and back pain.
What is the duration of daratumumab treatment?
Each cycle is of 28 days. Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
What is dardaratumumab subcutaneous (SC) injection?
Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion.
How is dardaratumumab administered for the treatment of multiple sclerosis (MS)?
Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
What is the difference between Cmax and Cmin for daratumumab?
PK concentration of Daratumumab will be measured. The Cmax is the maximum observed plasma concentration of Daratumumab. The Cmin is the minimum observed plasma concentration of Daratumumab.